NICE recommends Lucentis (Novartis) for Choroidal Neovascularization

NICE has issued final draft guidance recommending Lucentis (ranibizumab), from Novartis, as a treatment option for sight problems caused by new blood vessels growing at the back of the eye in people with Choroidal Neovascularization due to pathological myopia. The independent Committee concluded that the recommendations can go straight to a final draft, without the need for public consultation, which will help speed up access to this treatment.